Key Points of Emphasis Surrounding CDK4/6 Inhibitor in mBC Treatment

Opinion
Video

With their final thoughts, the panelists provide key takeaways from their conversation regarding CDK4/6 inhibitor therapy in treatment of HR+/HER2- metastatic breast cancer.

Ryan Haumschild, PharmD, MS, MBA: Thank you all for your expert insights. It’s been so valuable [with] so many lessons learned throughout the day. But before we conclude, I’d like to get final thoughts from each of you. Let’s start with you first, Dr Moore. What are some of your final thoughts for our viewing audience?

Heather Moore, CPP, PharmD, BCOP: I’m going to break them down into bullet points. One, I’d say it’s important to address the patient who is in front of you, finding the best agent for care from both a toxicity standpoint [but] also...an efficacy standpoint. I personally am really excited about the treatment paradigm and the changes that we’ve seen. I think we hit on this a little bit. We talk about adding therapies and targeted therapies, but another unmet need that may be helpful moving forward, how we de-escalate therapy in some of these patients, and sometimes do we need the therapy that we’re giving them? It’s important as we move forward, thinking about targeted therapies, how do we reduce the amounts of toxicity? How do we increase efficacy? Just thinking about the journey for these patients and how we do better from both an efficacy standpoint, but also prolonging their life, [and] also having quality of life, too?

Ryan Haumschild, PharmD, MS, MBA: Excellent. Great comments and great summary. How about you, Dr DiMarco? What are some of your final thoughts from today?

Rose DiMarco, PharmD, BCPS, BCOP: Sure. I just want to say I’m very passionate about quality. Reducing health care inequities is something that I think about every day. It’s great that we were able to talk so much about quality of life. What I want to see in the future is that we can elevate the role of the pharmacist in how we deliver quality care and just see where that goes. We’re excellently placed for doing this kind of work, and I don’t think the world knows it just yet.

Ryan Haumschild, PharmD, MS, MBA: Our role continues to expand, but what an exciting time for us and for patients. We’re such a key part of the decision-making process. Dr Kettle, your final thoughts?

Jacob K. Kettle, PharmD, BCOP: I’ve learned a lot just listening from you all today. I think, especially now in my larger, more administrative role, the thing that really motivates me is seeing the change in the care opportunities we have, the evolving role of the pharmacist. We’re really shifting away from…one of the common metaphors [of] it’s a fight, it’s a battle. Really trying to shift the mindset to think about [how] this is a journey. It’s a long process. We really, especially in metastatic breast cancer, [with] all the emerging therapies we’ve discussed today, we have a real, incredible power as pharmacists to impact and guide and shape that patient journey so that it’s as good as it can possibly be. Yes, maybe the patient’s goal of a cancer-uninterrupted life is gone, but that doesn’t mean we can’t deliver a really high quality of life and really optimize the journey. That’s really the most exciting thing to me and the most rewarding thing, is just seeing that shift in the way we approach these patients [as well as] the ability to really deliver a different experience and a higher quality for them.

Ryan Haumschild, PharmD, MS, MBA: Excellent. I’d like to thank the audience for viewing this educational program. Have a great day, everybody.

Transcript is AI generated and edited for clarity and readability.

Related Videos
Video 14 - "Closing Remarks on RSV Vaccinations"
Video 13 - "Understanding RSV Infection Patterns and Seasonal Outbreaks"
A panel of 4 experts on breast cancer
A panel of 4 experts on breast cancer
A panel of 4 experts
A panel of 4 experts
Video 12 - "Empowering RSV Patients: Essential Vaccine Education Resources"
Video 11 - "Unmet Needs in Prevention and Management of RSV"
A panel of 5 experts on ASCVD
A panel of 4 experts
© 2024 MJH Life Sciences

All rights reserved.